Recent studies have suggested that scorpion venom induces a catecholamine surge that leads to multiple cardiovascular responses, including hypertension, tachycardia, pulmonary edema, and even cardiovascular collapse, especially in children and the elderly. Previously, scorpion venom had been thought to cause only direct organ effects. Currently, scorpion antivenom may be used to combat the direct effects of venom, but cannot reverse the catecholamine response once it has commenced. This study was designed to clarify the true mechanism of action of scorpion venom: catecholamines should be exhausted from the first envenomation, and thus any response to a second envenomation should be secondary to direct effects of the toxin.
This animal study was completed on 20 anesthetized dogs, with 15 receiving doses of scorpion venom (Androctonus australis hector), and 5 animals serving as sham controls. The first dose of venom administered consisted of a sublethal dose of 0.05 mg/kg. Plasma toxin and catecholamine levels, as well as hemodynamic measurements such as cardiac output, stroke volume, and vascular resistance, were measured multiple times in the first hour after administration. A second dose of venom (one-half sublethal dose) was then given to 5 dogs 30 minutes after the first, with all measurements repeated 5 minutes after dosing.
Levels of venom toxin were similar in both groups (single envenomation and double envenomation). In the single envenomation group, there was an immediate large increase in catecholamines (norepinephrine and epinephrine), a slight fall in heart rate, and an increase in systemic vascular resistance. The double envenomation group had a similar venom toxin level, but did not have any physiologic measurements suggestive of catecholamine response. Catecholamine levels actually declined despite the second envenomation.
The authors theorize that the lack of a cardiac response after the second envenomation indicates that catecholamines are significant mediators in the hemodynamic effects of the venom. In addition, the lack of a second catecholamine release indicates either that the receptors are saturated or that catecholamine stores have been depleted. The study raises the question of whether antivenom is an effective treatment in preventing cardiovascular collapse once the catecholamine cascade has started. Although neutralizing the toxin may be helpful in the first 30 minutes after envenomation, future treatments may be directed at providing competition at the catecholamine receptor site to prevent subsequent effects of the circulating catecholamines.
( Ankle ligament sprains are the single most common sports injury, accounting for 19% to 23% of all sports injuries presenting to accident and emergency (A&E) departments in Scotland. About 90% are inversion injuries affecting the lateral ligament complex. Ankle sprains have been classified into grades I, II, and III according to macroscopic appearance and clinical findings, or mild, moderate, and severe, respectively. Despite the high incidence of ankle sprains, there is no uniform approach to their management. The aim of this study was to determine the functional outcome of the ankle joint after a moderate or severe inversion injury, comparing standard treatment with an elastic support bandage with the application of a semi-rigid ankle brace manufactured by Aircast. Mild ankle sprains were not included in this study.
Fifty consecutive adult patients (16 years and over) presenting within 24 hours of sustaining a moderate or severe lateral ligament sprain after an ankle inversion injury were randomized into 2 equal groups and each patient was allocated to use either an elastic support bandage or an Aircast ankle brace. Fracture was excluded by x-ray examination. All patients included in the study were given a standardized advice sheet referring to the principles of ''RICE'' therapy (rest, ice, compression, and elevation). Analgesia and crutches were given as required. Patients were re-evaluated after 48 to 72 hours, 10 days, and 1 month. The primary outcome measured was ankle joint function. This was assessed at 10 days and 1 month using a modified version of the Karlsson scoring scale, a statistically validated scoring scale that can be used to measure ankle joint function in the rehabilitation phase after an acute ligament injury-a higher score indicating better joint function. Secondary outcome measures, recorded at 10 days only, consisted of the difference in ankle swelling between the injured/uninjured ankles and the difference in pain scores compared with initial presentation.
Seventeen patients in the elastic support bandage group and 18 patients in the Aircast ankle brace group completed the study. There were no significant differences between the 2 groups at presentation in terms of age (mean 35.3 and 32.6 years respectively), sex, dominant leg, left or right ankle injured, previous injury, time to presentation (median 3 and 4 hours respectively), difference in ankle swelling, and pain scores. The Karlsson score was significantly higher in the Aircast group than in the elastic bandage group at 10 days (mean 50 vs 35), and 1 month (mean 68 vs 55). There was no difference between the groups in the secondary outcome measures. When hierarchical multiple regression analysis was used to correct for possible baseline confounding factors, the Aircast group was significantly associated with higher Karlsson scores at 10 days and 1 month.
The results of this small study only prove that the Aircast ankle brace is superior to an elastic support bandage in improving functional outcome. It does not prove that patients treated with an elastic support bandage derived no benefit. Intuitively, both groups had a higher Karlsson score at 1 month than at 10 days, suggesting that, independent of the treatment used, the injury will improve progressively with time. There are many short and long term benefits to the Aircast including the capability for reuse, patient's ability to wear it during rehabilitation, and the ease of stuffing it into a backpack for a hiking trip. This study suggests that an Aircast should be a basic addition to a backcountry medical kit, and its use should be encouraged early after an injury. Leishmaniasis, a disease caused by a protozoan parasite, presents with a wide range of clinical manifestations that range from skin ulcers to visceral infection. The largest worldwide focus of cutaneous leishmaniasis (CL), found in Kabul, Afghanistan, has an annual caseload of 67 500 to 200 000 patients. The causative agent in this area, Leishmania tropica, is transmitted by the sand fly, Phlebotomus sergenti, and has an incubation period of 2 months to 2 years. This species causes ulcers with heaped margins and a granulomatous base that is usually 1 to 2 cm in size. Spontaneous resolution takes 1 to 2 years. The standard treatment is either intramuscular (IM) or intralesional (IL) injections of a pentavalent antimonial, sodium stibogluconate (SSG). Antimonials are expensive and have many complications, including pancreatitis, hepatotoxicity, and cardiotoxity. The side effects from the antimonials, as well as a lengthy dosing regimen, have led to low compliance and the development of drug resistant strains. The purpose of this study was to determine if treatment with thermotherapy was as effective as intralesional or intramuscular injections of SSG for cure of cutaneous leishmaniasis.
This randomized, controlled trial included participants with only 1 CL lesion, no prior history of disease or treatment, and no lesions near the lips or the eyes. Lesions were confirmed by microscopic exam and polymerase chain reaction (PCR). The participants were randomized to 1 of 3 treatments: intralesional SSG injections every 5 to 7 days for 29 days, daily IM injections of SSG of 20 mg/kg up to a max of 850 mg for 21 days, or 1 treatment of thermotherapy. Thermotherapy uses an applied radiofrequency to increase the temperature of the upper dermis without injuring underlying healthy tissue. The study ended 100 days after the beginning of treatment. Efficacy was determined by the number of patients cured at the end of 100 days, as well as the time to cure.
Of the 431 patients enrolled, 259 completed the study. There was a cure rate of 69% in the thermotherapy group (108 patients), defined as complete re-epithelization of the lesion. The IM SSG group (58 patients) had a cure rate of 45% and the IL group (93 patients) had a cure rate of 75%. The paucity of patients in the IM group was largely due to participant withdrawal after being randomized. No statistical differences existed between the groups for age, sex, body weight, lesion size, or lesion duration. The thermotherapy (P ϭ .002) and the IL (P ϭ .001) groups had significantly greater cure rates than the IM group although 47% of the IM group was dose-limited by protocol. While the thermotherapy and IL groups were equally efficacious, the time to cure was significantly shorter (P ϭ .003) in the thermotherapy group (53 vs 75 days). Seconddegree burns and an increase in lesion size were the major complications of thermotherapy, occurring immediately following treatment and for up to 2 weeks afterwards.
According to this study, a single treatment of thermotherapy is as effective as a course of IL SSG and more effective than IM SSG. Time to cure was shorter with the thermotherapy than with SSG. Advantages of both IL SSG and thermotherapy are a decrease in drug dose and toxicity when compared to IM SSG. The major advantage of thermotherapy is that it only involves 1 treatment, which could improve compliance and decrease the incidence of drug resistant species. The disadvantages are that it does not treat mucosal lesions, lesions near the eyes and lips, or visceral disease, and the initial cost of the thermotherapy device is over $20 000 (USD). L tropica is known to be a temperature resistant species, so thermotherapy may be more efficacious when used against other types of leishmaniasis. This study demonstrates thermotherapy to be a cost-effective, efficacious, and safe alternative to antimonials for treatment of cutaneous leishmaniasis in areas of high prevalence, once the expensive equipment has been purchased. 
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The Effects of a 5-Lipoxygenase Inhibitor on Acute Mountain Sickness and Urinary Leukotriene E4 After Ascent to High Altitude
Past studies have shown urine and blood levels of leukotrienes to be present after ascent to high altitude. These inflammatory mediators have been implicated in acute mountain sickness (AMS) and high altitude pulmonary edema (HAPE), and are thought to increase permeability of cell membranes in brain and lungs. However, additional studies have suggested that leukotriene synthesis is induced by AMS, and is thus a result of the condition rather than its cause. This randomized, placebo-controlled trial was designed not only to prove the causal relationship of leukotrienes in AMS, but to also see if an inhibitor of 5-lipoxygenase, zileuton, could help prevent AMS and HAPE in mountaineers going to high altitude.
The study was completed during the 1998 climbing season on Mt McKinley in Alaska. Nineteen climbers were recruited in Talkeetna, prior to their ascent to base camp. Exclusion criteria included previous AMS or the use of prophylactic medications against AMS. Baseline urine samples were taken in Talkeetna, and were repeated at 4200 meters at the West Buttress camp after each individual arrived there from 2300 meters. All urine samples were flown to the University of Utah for analysis of leukotrienes. Climbers were blindly randomized to receiving zileuton 600 mg 4 times daily or placebo, beginning the day prior to their ascent from 2300 meters.
Eighteen subjects completed the study, with 9 randomized to zileuton and 9 randomized to placebo. Urinary leukotrienes actually decreased in both the zileuton and placebo groups after ascent to high altitude. Even the 1 subject in the zileuton group and the 3 subjects in the placebo group diagnosed with AMS by Lake Louise criteria had decreased levels of urinary leukotriene compared to baseline samples taken in Talkeetna. A decrease in leukotrienes had been expected in the zileuton group due to its inhibition properties, but there was an unexpected decrease in leukotrienes in the placebo group as well.
Although this study was small and lacked sufficient subjects to be a definitive work on the subject, it does suggest that the inflammatory mediator family of leukotrienes does not cause AMS. Despite many theories and past clinical trials, researchers are still unclear as to the true etiology of AMS. However, since there appears to be a component of increased cellular permeability involved in AMS, and inflammatory mediators are often involved in changes of cellular permeability in other physiologic processes, other inflammatory mediators will undoubtedly be studied in the future. Anterior shoulder dislocations, which account for over 95% of all shoulder dislocations, have a reported lifetime incidence of up to 2%. Many outdoor sports, such as rock climbing, mountain biking, and kayaking carry an increased rate of anterior shoulder dislocations. Previous data have shown that patients less than 30 years old at the time of dislocation have significantly higher rates of subsequent recurrent dislocation and disease-specific morbidity. This prospective, randomized, clinical trial compares immediate surgical stabilization with a trial of immobilization and rehabilitation in young patients (Ͻ30 years old) for a first-time anterior shoulder dislocation. The goal of the study was to assess differences in the rate of subsequent dislocation, in disease-specific quality of life, and to look for any adverse effects of waiting for a second dislocation to perform shoulder surgery.
Forty patients under 30 years old who had sustained a first traumatic anterior dislocation were included in the study. Anterior dislocations were defined by the mechanism of abduction and external rotation, sudden pain in the shoulder, and radiographic evidence of dislocation or required reduction. Patients were excluded from the study if there was neurovascular compromise of the affected limb, a history of ipsilateral multidirectional instability of the joint, current contralateral joint instability, medical reasons to make the patient a poor surgical candidate, or if the patient was unwilling to be followed-up for 5 years. The surgery group underwent transglenoid suturing, with anterior labral fixation if needed, within 4 weeks of initial injury. Following the procedure, patients received treatment identical to the control group, which included 3 weeks of immobilization and 9 weeks of physical therapy. All patients were allowed limited participation in sports at 3 months post injury and full participation, as tolerated, at 16 weeks. Patient outcome was determined primarily by the Western Ontario Shoulder Instability Index (WOSI), as well as the American Shoulder and Elbow Surgeons (ASES) form and the Disabilities of the Arm, Shoulder, and Hand (DASH) form. These surveys derive information about patient function, quality of life, and pain, in addition to incorporating physical assessment of the shoulder by 1 of the researchers. The research assistants that performed the examination were blinded to the treatment group as the patients were instructed to wear long sleeve shirts upon follow-up that would cover any potential scars.
Of the original patients, 31 were found and agreed to reevaluation: 16 in the surgical group and 15 in the control group, with an average follow-up time of 79 months. There was no significant difference between the 2 groups in age, gender, hand dominance, or whether the injury was sports related. Previously published data from these patients showed a favorable WOSI score for the surgical treatment group at the 32-month time point. However, the current paper shows that at 79 months there was no significant difference in WOSI, ASES, or DASH scores between the 2 groups. By 32 months, there were 3 surgically treated patients and 9 control patients that had dislocated their shoulder for a second time, resulting in 7 of the non-surgical patients receiving surgical stabilization. There were no additional patients in either group that dislocated their shoulder between 32 months and the long-term follow-up.
Immediate surgical stabilization of the shoulder does appear to decrease the rate of, but not prevent, recurrent dislocation in this young population. There is a significant portion of the patients that undergo conservative treatment of immobilization and rehabilitation, and have not dislocated at 79 months. These data suggest that performing surgery on all patients less than 30 years old with their first dislocation would result in many unnecessary procedures. The WOSI, ASES, and DASH data for the control group were comparable to the surgical group suggesting that initial conservative treatment with or without delayed surgery may not adversely affect quality of life or shoulder function. The recommendations from these data for treatment of a first anterior dislocation in a young person would be to perform surgery if the patient is at high risk for repeat dislocation, such as a high level outdoor athlete (mountain biker, rock climber, kayaker, parachuter) where a shoulder dislocation could be extremely detrimental and possibly lifethreatening. For patients with less risk, immobilization with rehabilitation is still the treatment of choice, with surgical stabilization reserved for those with a second dislocation. Increasing numbers of people are participating in snowboarding, which is a high velocity sport associated with injuries secondary to rapid deceleration. Fractures of the upper extremities and blunt abdominal injuries are known patterns of injury associated with snowboarding, and Canadian physicians have even penned the term ''Boarder Belly'' to describe splenic injuries secondary to the sport. This review examines rates of splenic injuries in both snowboarders and skiers, with special attention on gender differences and mechanism of injury in the 2 groups.
Canadian researchers conducted a 10-year retrospective review of splenic injuries caused by snowboarding or skiing that were seen at 2 hospitals near several British Columbia ski resorts. Splenic injuries were diagnosed in the operating room, on ultrasound, or by abdominal CT scan. Reviewers extracted demographics, mechanism of injury, activity during injury (skiing or snowboarding), coexistent injuries, and treatment type from hospital charts. In addition, at-risk population data were acquired from the Canadian Ski Council in order to determine rates of occurrence of splenic injury.
During the 10-year study period, 65 of 178 splenic injuries at the study hospitals were attributed to snowboarding or skiing accidents (snowboarding ϭ 43, skiing ϭ 22). Diagnosis of splenic injury was made in the operating room once, by ultrasound in 13 patients, and by abdominal CT scan in the remaining 51 patients. Forty-two of the 43 snowboarding patients were men, while 17 of 22 injured skiers were men. Mechanism of injury to snowboarders was most likely to be from jumps and falls, while skiers were injured in collisions. Snowboarders were found to have a 6-fold increased risk of splenic injury when compared to skiers (P Ͻ .0001) and men were 22 times more likely to sustain this injury than women (P Ͻ .002).
Although this study did miss some splenic injuries (those sent home by the resort clinic or those flown to an alternative trauma center outside the catchment area), the data show that snowboarders are at more risk for splenic injuries secondary to blunt abdominal trauma than skiers. It is unclear from this study whether snowboarding is more dangerous than skiing, or if the sport just attracts more high-risk individuals (young men). However, patterns of injury attributable to snowboarding such as jumping and falling after catching an edge can cause severe blunt abdominal trauma and should increase the level of suspicion for splenic injuries by both ski patrollers and health care providers seeing injured snowboarders.
